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Abstract 
 
Background and aims: We aimed to examine, for the first time, the effect of 
cannabidiol (CBD) and palmitoylethanolamide (PEA) on the permeability of the human 
gastrointestinal tract in vitro, ex vivo and in vivo. 
Methods: Flux measurements of FD10 and FD4 dextran across Caco-2 cultures treated 
for 24hr with IFNγ and TNFα (10ng·mL-1) were measured, with or without the presence 
of CBD and PEA.  Mechanisms were investigated using CB1, CB2, TRPV1, and PPARα 
antagonists, and PKA, NOS, PI3K, MEK/ERK, adenylyl cyclase and PKC inhibitors.  
Human colonic mucosal samples collected from bowel resections were treated as above.  
TRPV1, PPARα, PPARδ, PPARγ, CB1, CB2, GPR55, GPR119, and claudins -1,-2,-3,-4,-5,-7, 
and -8 mRNA were measured using multiplex. Aquaporin 3 and 4 were measured using 
ELISA. A randomised, double blind controlled-trial assessed the effect of PEA or CBD on 
the absorption of lactulose and mannitol in humans taking 600mg aspirin.  Urinary 
concentrations of these sugars were measured using liquid chromatography mass 
spectrometry.  
Results: In vitro, PEA and CBD decreased the inflammation-induced flux of dextrans 
(p<0.0001), sensitive to PPARα and CB1 antagonism respectively. Both PEA and CBD 
were prevented by PKA, MEK/ERK and adenylyl cyclase inhibition (p<0.001). In human 
mucosa, inflammation decreased claudin-5 mRNA, which was prevented by CBD 
(p<0.05). PEA and CBD prevented an inflammation-induced fall in TRPV1 and increase in 
PPARα transcription(p<0.0001). In vivo, aspirin caused an increase in the absorption of 
lactulose and mannitol, which was reduced by PEA or CBD (p<0.001). 
Conclusion: CBD and PEA reduce permeability in the human colon. These findings have 
implications in disorders associated with increased gut permeability, such as 
inflammatory bowel disease. 
Keywords: human, permeability, intestinal, cannabidiol, palmitoylethanolamide  
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Introduction 
The gut provides a barrier between the external and internal environment.  This 
selectively permeable barrier allows absorption of nutrients and water from 
gastrointestinal contents, whilst preventing the transfer of noxious material such as 
bacteria and lipopolysaccharide. During episodes of inflammation, the barrier becomes 
compromised, allowing transfer of noxious material into the systemic circulation, leading 
to disease states such as inflammatory bowel disease (IBD) and septic shock 1.   
The use of cannabis sativa for its analgesic and anti-inflammatory effects have been well 
described 2.   Interest in the psychoactive properties of cannabis sativa lead to the 
characterisation of its active major compounds Δ9-tetrahydrocannabinol (THC) and 
cannabidiol (CBD) and approximately eighty other compounds 3,4.  Discovery of the 
receptors for these ligands followed, with cloning of the CB1 and CB2 receptors 5,6.  The 
endogenous ligands anandamide and 2-arachiodonoylglycerol which act at these 
receptors have been well described 7–9.  Endocannabinoid-like compounds acting 
alongside these such as palmitoylethanolamide (PEA)  have emerged, with affinity for 
receptors such as the GPR55 receptor, and the nuclear peroxisome proliferator activated 
receptors (PPARs) 10–12.  PEA is widely used as a food additive and is being assessed for 
clinical use in pain and inflammation 13,14.  Similarly, CBD is already in use the treatment 
of multiple sclerosis (as part of the medicine Sativex), and by itself in childhood epilepsy 
15,16.   
We previously demonstrated that inflammation causes an increase in the permeability of 
fully confluent Caco-2 monolayers, measured by trans-epithelial electrical resistance 
(TEER)17.  We identified that application of CBD or PEA rescued falls in TEER (i.e. reduces 
inflammation-induced increases in permeability).  The effects of CBD were blocked by 
antagonism of the CB1 receptor, while PEA was blocked by antagonism of the PPARα 
receptor 17,18.  Our recent meta-analysis demonstrated that preclinical studies with both 
CBD and PEA show promise in animal models 19.   
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In light of this background, we hypothesised that CBD and PEA reduce inflammation-
induced permeability in the human gut, and here examined the effects of PEA and CBD 
on the human colon using Caco-2 cells and ex vivo human colonic tissue, identifying 
their mechanisms of action. Based on these positive findings, we went on to examine the 
potential of CBD and PEA to modulate intestinal permeability in humans in vivo using a 
randomised controlled trial.    
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Materials & Methods 
In vitro permeability studies  
Caco-2 cells were purchased from European Collection of Cell Culture (Wiltshire, UK; 
passages 21-42).  Cells were cultured in Eagle’s minimum essential medium 
supplemented with L-glutamine, 10% foetal bovine serum (FBS) 1% 
penicillin/streptomycin and 1% non-essential amino acids mixture (all Sigma-Aldrich).  
Cells were kept at 37°C in 5% CO2 and 95% humidity.  For permeability experiments 
cells were seeded at 5x104/ml per well in the apical compartment of 12mm diameter 
3.0µm pore polyester membrane inserts within polyester 24-well plates (Corning 
Incorporated, ME, USA), and cultured for 14-16 days until fully confluent.   Randomly 
assigned wells (n=8) were treated with or IFNγ (basolateral, 10 ng.ml-1, Sigma-Aldrich) 
for 8 hours, followed by TNFα (basolateral, 10 ng.ml-1, (Sigma-Aldrich)) for 16 hours to 
induce inflammation. PEA (basolateral, 10µM, Tocris Bioscience, Bristol UK), CBD (apical, 
10µM, Tocris Bioscience, Bristol UK) or vehicle (0.01% ethanol) were added with or 
without inflammation at the start of the 24 hour experimental period. Drug 
concentrations were based upon previous experiments 17. 
Confluent monolayers cultured on membrane inserts were washed three times with pre-
warmed PBS.  Clear, non-fluorescent media (FluoroBrite DMEM, ThermoFisher Scientific 
MA, USA) supplemented with 1% nonessential amino acids and 1% 
penicillin/streptomycin was added to both the apical (225µl) and basolateral 
compartment (700µl) as per manufacturer’s instructions and left for 30 minutes to 
equilibrate.  FD4 and FD10 fluorescent dextrans (FDs; 25 mg.ml-1) were then added to 
the apical compartment.  At 37°C, baseline (0hr) the fluorescence of 100-µl aliquot 
basolateral samples were determined (Fluoroskan Ascent FL2.5, ThermoFisher Scientific, 
Waltham, MA, excitation and emission wavelengths of 485 and 520 nm respectively).  
Fluorescence was determined at regular intervals for 36 hours.  
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PEA and CBD we co-applied with antagonists under inflammatory conditions: AM251 
100nM (CB1 antagonist, Tocris Bioscience, Bristol, UK), AM630 100nM (CB2 antagonist, 
Tocris Bioscience, Bristol, UK), GW6471 500nm (PPARα antagonist, Tocris Bioscience, 
Bristol, UK), and SB366791 500nM (transient receptor potential vanilloid 1 (TRPV1)) 
antagonist, Tocris Bioscience, Bristol, UK).  We co-applied various inhibitors with PEA or 
CBD under inflammatory conditions: KT5720 (Protein kinase A (PKA) inhibitor, 1µM, 
Tocris Bioscience, Bristol, UK), L-NAME (NOS inhibitor, 10µM, Tocris Bioscience, Bristol, 
UK), PD98059 (MEK/ERK inhibitor, 10µM, Tocris Bioscience, Bristol, UK), SQ22536 
(adenylyl cyclase inhibitor, 1µM, Tocris Bioscience, Bristol, UK) and G06983 (PKC 
inhibitor, 1µM, Tocris Bioscience, Bristol, UK). 
mRNA and Protein expression 
Caco-2 cells were cultured in 6-well plates (Corning Incorporated, ME, USA) for 14 days.  
Following 24 h treatments with CBD or PEA, cells were washed twice with ice-cold 
phosphate buffered saline (PBS), and treated with radioimmunoprecipitation assay 
(RIPA) buffer containing phosphatase inhibitor and protease inhibitors (Sigma-Aldrich) at 
4°C for one h on a rocking platform to cause cell lysis.  Cell lysates were then collected 
and stored at -80 °C until analysis.  
 
Experiments on ex vivo human colonic tissue were performed on healthy colonic tissue 
taken from colon removed at elective resection for bowel cancer at Royal Derby Teaching 
Hospital NHS Trust, Derbyshire (n=8).  After informed consent, samples of 
macroscopically normal colon at least 10cm proximal or distal to any bowel tumour were 
obtained immediately after resection within the operating theatre.  Ischaemic times 
following pedicle clamping were not recorded.  Sections of tissue 2cm x 2cm were 
excised and transferred on ice to the laboratory within ten minutes, in pre-chilled Eagle’s 
minimum essential medium supplemented with 1% FBS, 1% penicillin/streptomycin and 
1% non-essential amino acids mixture (Sigma-Aldrich).  Mucosa with submucosa was 
dissected free from the underlying muscularis layer.  Samples were further dissected into 
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~2mm x 2mm sections and placed in individual wells of 24-well polystyrene plates 
(Corning Incorporated, USA) at 37°C in 5% CO2 and 95% humidity, and treated with PEA 
and CBD.  After 24 h, the tissue was washed with ice cold PBS and stored frozen at -80 
°C until homogenisation and analysis.  Samples were cryohomogenised as previously 
described by von Zeigler 20. Collected homogenates were then dissolved in 100µl of RIPA 
buffer containing phosphatase inhibitor and protease inhibitor (Sigma-Aldrich), incubated 
on an oscillating thermomixer for 30 minutes at 60 °C, and then centrifuged at 10,000G 
for 15 minutes.   
mRNA levels of PPARγ, PPARα, PPARδ, GPR55, GPR119, CB1, CB2 and TRPV1 were 
determined using Quantigene Plex kit QP1013, claudin -1,-2,-3,-4,-5,-7 and-8 were 
determined using kit QP101 and a Magpix (MAGPX 11326002, Luminex, Texas US).  
mRNA levels were normalised according to levels of three housekeeping proteins β-actin, 
peptidyl-prolyl cis-trans isomerase B (PPIB), and hypoxanthine 
phosphoribosyltransferase 1 (HPRT1), which did not change in expression under the 
inflammatory protocol.  
Membrane-bound AQP cell membrane fractions were prepared with Mem-PER Plus kit 
(#89842, ThermoScientific). ELISA for aquaporin-3 (AQP3) and aquaporin-4 (AQP4) 
were performed as per manufacturer’s instructions (#LS-F13079 & #LS-F13078, 
Lifespan Biosciences, WA USA), and normalised by mean protein content or cell-
membrane supernatants using a bicinchoninic acid assay (Sigma-Aldrich).  
Randomised, placebo controlled, double-blind controlled trial  
In healthy human subjects we induced a state of increased gut permeability with aspirin, 
measuring the urinary concentrations of sugar probes.  Participants were treated with 
oral PEA and CBD, and the change in gut permeability measured in a randomised 
double-blind, controlled trial. All experiments and procedures received prior approval of 
the University of Nottingham Ethics Committee (approval number J16122016), this trial 
was not registered on a trials registry.  Healthy male participants between the ages of 18 
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and 50 were recruited after informed consent.  Participants were screened to exclude 
any gastrointestinal medical conditions or symptoms, regular medications or recreational 
drugs, heavy alcohol use, previous abdominal surgery, or personal or family history of 
IBD.  Participants were asked to refrain from the use of any pro or prebiotics the week 
before the study, and refrain from alcohol or non-steroidal anti-inflammatory use or 
heavy exercise for three days before the study. Participants separately attended fasted 
at 08:00.  Aspirin 600mg was administered orally with 400mls water with CBD 600mg, 
PEA 600mg or placebo.  At 09:00 1g lactulose and 1g mannitol in 600ml water were 
further administered, then a baseline urine sample was collected. Urine was collected 
hourly for 5 hours until 14:00. A further 400ml water was administered at 12:00.  
Urinary samples were immediately centrifuged at 1,000G for 7 minutes at 3°C and then 
frozen at -80°C until analysis.  
Based on previously published literature a sample population under the same 
experimental conditions demonstrated a urinary lactulose-mannitol ratio (LMR) of 0.81 
when treated with aspirin, verses an LMR of 0.053 (SEM=0.02) 21.  Based on α=0.05 
using a paired t-test (effect size = 1.0) it was calculated that to detect a difference in 
LMR of 0.02 between treatment and placebo arms with a power of 80% and α of 0.05, a 
sample size of 10 patients was required, should a difference exist between the treatment 
and placebo groups.  Using the block method in a 1:1:1 ratio participants were assigned 
to receive CBD, PEA or placebo.  Both participants and investigators were blinded to the 
group assignments.  Participants were numbered sequentially and were assigned to the 
treatment groups in the order of recruitment.  Code assignment was sealed within an 
envelope until after the samples were analysed.  Participant assignment was only 
revealed at the end of the study.  
CBD was gifted from Artelo Biosciences (CA, USA), extracted from cannabis sativa, and 
analysed at an independent laboratory to assure >99.65% purity.  PEA was obtained 
from Russel Science (Nicosia, Cyprus).  Placebo were manufactured and gifted by Artelo 
Biosciences using the base cellulose used in the preparation of CBD.  Aspirin was 
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obtained from Aspar Pharmaceuticals (London, UK). Lactulose was obtained from TEVA 
(Castleford, UK).  D-mannitol was obtained from Sigma Aldridge (MO, USA).  All 
products used in the test solution were intended for human use and tested safe for oral 
consumption.  The purity of these sugar probes were reported to be >99.0%. 
Concentrations of urinary lactulose and mannitol were determined using a liquid LC-MS 
method.  20µl aliquots of urine were thawed and diluted to precipitate any excess salt 
with 980µl 90% acetonitrile to which internal standards xylitol and raffinose were 
premixed at 0.5µg/ml final concentration. These were vortexed, incubated at -20⁰C for 
4hours. Previous work demonstrated that it is necessary to monitor sucrose to ensure 
the assay is specific, correctly identifying lactulose, and therefore included as an analyte 
22. Calibration standards were made as a dilution series from 2.5 to 250µg/ml of the 
analytes mannitol and lactulose. The method had been previously validated by creating 6 
independently prepared dilutions of 5, 50 and 500µg/ml as above 22. The LC method was 
based on that of Kubica 23. The LC column was a Sequant ZIC-pHILIC pHILIC (150 x 
4.6mm, 5µm) kept at 40⁰C. The mobile phases were A, acetonitrile and B, 5mM 
ammonium acetate, adjusted drop-wise to pH6.85 with 5mM ammonium hydroxide 
solution. B Samples were kept in a chilled auto-sampler and 2µl volumes were injected 
for analysis.  The detector was a Sciex 4000 QTrap operating in -ve ion electrospray 
mode at with the source at 450⁰C with curtain, nebuliser and auxiliary gases set to 10, 
40 and 20 respectively. The ion-spray voltage was -4200V.  A minimum of 5 points were 
used for each analyte.  Xylitol was used as the internal standard to normalise the 
lactulose signal but the raw peak area was used to calculate the mannitol 
concentrations. Raffinose had been included as an internal standard as it has been used 
in previous studies 22,24. A standard prepared at 50µg/ml was injected every 20 samples 
was used to monitor precision and accuracy.  The CVs were 14.1 and 7.3 for lactulose 
and mannitol respectively. The precisions were 107 and 89%. Calibration lines are linear 
over a range greater than 2.5 to 250µg/ml with R2 >0.9995 for both analytes.  
Statistical analysis 
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For in vitro and ex vivo experiments data are presented as mean (or mean percentage) 
change from baseline where indicated ± standard error of the mean (SEM).  Permeability 
study results were compared using two-way ANOVA. Caco-2 and human tissue group 
results were compared using one-way ANOVA.  The calculated concentration of each 
urinary sugar was assessed by repeated-measures ANOVA, with probabilities of post hoc 
comparisons subject to the Bonferroni correction.  The differences in excretion of 
lactulose and D-Mannitol over the study period were compared using two-way ANOVA.  
Normality was assessed using the D’Agostino & Pearson normality test. A p-value of 
<0.05 was considered statistically significant.  All statistical analyses were performed 
using GraphPad Prism 7.01 for Windows (GraphPad Software, San Diego, USA). All 
authors had access to the study data and reviewed and approved the final manuscript. 
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Results 
Dextran-transfer studies 
Within Caco-2 cultures, inflammation caused an increase in the transfer of labelled FD4 
and FD10 dextrans from 2 and 4 h respectively (p<0.0001), until the end of the study 
period at 36 h (figures 1 A and B). PEA, in the presence of inflammation, reduced FD4 
transfer compared to inflammation from 4 hours (p<0.01, fig 2A), increasing with time, 
with the maximal difference seen at 12 h (p<0.0001).  For FD10, PEA in the presence of 
inflammation caused a reduction in the transfer of dextrans compared to inflammation 
from 4 h p<0.0001, figure 1 B) until 36 h. Antagonism of the PPARα receptor (but not 
TRPV1, CB1 and CB2) blocked the ability of PEA to reduce transfer of FD10 dextran over 
the study period (figure 2 A). The effect of PEA in reducing the transfer of dextrans was 
also blocked by various intracellular signalling inhibitors; KT5720 (PKA inhibitor), 
PD98059 (MAPK inhibitor) and SQ22563 (adenylyl cyclase inhibitor, p<0.0001, figure 3 
C and D), but not by L-NAME (nitric oxide synthase inhibitor), LY294002 (PI3 kinase 
inhibitor), or G06983 (PKC inhibitor, figure 3 C and D). 
CBD in the presence of inflammation caused a reduction in dextran transfer of FD4 
compared to inflammation alone from 4 h (p<0.01, figure 1 A).  This difference became 
more pronounced with time, with maximal difference seen at 8 h (p<0.0001).  With 
FD10, CBD in the presence of inflammation caused a reduction in the transfer of dextran 
from 4 h (p<0.0001, figure 1 B) until 36 hours.  Repeating in the presence of various 
antagonists revealed that only antagonism of the CB1 receptor blocked the effects of 
CBD (figure 2 B).  As with PEA, the effect of CBD on the transfer of dextrans was blocked 
by the presence of KT5720, PD98059 and SQ22563 but not L-NAME, LY294002 or 
G06983 (p<0.0001, figure 3 A and B).  When applied together PEA and CBD had no 
added effect on permeability in the presence of inflammation (figure 1 C). 
Effects of CBD and PEA on claudin and cannabinoid receptor expression 
Compared to vehicle, inflammation, PEA or CBD did not change the mRNA levels of 
claudins -1, -2, -3, -4, -5, 7, or -8 in Caco-2 cells (figures 4 A, 4 C and supplementary 
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figure 1 A-E).  Inflammation, CBD or PEA treatment did not affect the mRNA of claudins 
-1, -2, -4, -7, or -8 in human colonic tissue (supplementary figure 1 F-J).   
In human colonic tissue, PEA decreased claudin-3 mRNA levels both in the presence of 
inflammation and alone (p<0.01, figure 4 B). Inflammation decreased claudin-5 mRNA 
levels compared to control tissue (p<0.05 figure 4 D), and this was prevented by 
treatment with CBD (p<0.05) but not PEA.  PEA treatment alone also decreased claudin-
5 mRNA levels (p<0.05 figure 4 D). 
In Caco-2 cells, inflammation decreased TRPV1 mRNA levels (figure 5 A), which was 
prevented by PEA and CBD.  In human colonic tissue, inflammation caused a fall in the 
mRNA of TRPV1, prevented by CBD (p<0.05, figure 5 B).  Inflammation increased PPARα 
mRNA , but not by treatment with PEA or CBD (p<0.05, figure 5 D).  
Inflammation did not affect mRNA levels of PPARδ, PPARγ, PPARα, GPR55, GPR119, CB1 
or CB2 in Caco-2 cells or human colonic tissue (figure 5 C and supplementary figure 2 A-
L).   
Effects of CBD and PEA on membrane-bound AQP channels 
In Caco-2 cultures IFNγ and TNFα increased the presence of AQP3 (figure 6 A), and this 
was prevented by PEA (apical, p<0.05), or CBD (apical, p<0.05).  PEA or CBD alone did 
not affect AQP3 compared to control.  In human colonic tissue, inflammation did not 
change AQP3, though AQP3 levels were increased in the presence of inflammation and 
PEA, and also inflammation and CBD (p<0.01 and <0.001 respectively, figure 6 C).  PEA 
or CBD alone did not affect the levels of AQP3 in human mucosal tissue compared to 
vehicle.   
 
In Caco-2 cells the inflammatory protocol did not affect the presence of AQP4, though 
treatment with CBD or PEA alone did cause an increase in the presence of AQP4 
(p<0.05, figure 6 B).  IFNγ and TNFα increased the presence of AQP4 in human colonic 
mucosa (p<0.001), which was not affected by treatment with PEA or CBD, however 
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treatment of colonic mucosa with PEA or CBD alone decreased the presence of these 
proteins compared to vehicle (p<0.01 and <0.05 respectively, figure 6 D). 
 
Absorption and excretion of urinary sugars in vivo 
30 male participants aged between 22 and 51 years (median age 28.7) successfully 
completed the study.  No exclusions were made on the grounds of fitness.  No 
participants reported any side effects in experimental sessions.  Urinary concentrations 
of mannitol excreted over the 6-hour study period were normally distributed.   
In participants receiving placebo only, aspirin administration caused an increase in the 
urinary concentration of mannitol and lactulose over the 6-hour study period (p<0.0001 
and P<0.001 respectively, table 1).  Maximal increases in LMR were found at 2 hours 
following aspirin and placebo administration (p<0.0001 compared to baseline).   
In participants administered both CBD and aspirin, urinary lactulose and mannitol 
concentrations were also increased across the study period (p<0.001 and p<0.01 
respectively, table 1).  LMR across the experimental period was also increased (p<0.001 
compared to baseline), however compared to the placebo and asprin group LMR was 
reduced reaching maximal difference at 2 hours post-administration (p<0.0001, figure 
7). 
In the PEA and aspirin group, urinary lactulose, but not mannitol concentrations were 
also increased (p<0.01, table 1). In 6 patients in this group mannitol levels were 
undetectable at baseline and subsequent timepoints, and hence LMR was unable to be 
calculated.  These patients were excluded from the results. LMR across the study period 
was increased (p<0.01 compared to baseline).  Compared to the placebo and aspirin 
group LMR was reduced, reaching maximal difference at 3 hours post-administration 
(p<0.001, figure 7). There was no difference in significance between PEA and CBD in 
reduction of LMR compared to placebo. 
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Discussion 
The aims of this study were to assess the effect of PEA and CBD on the permeability of the 
human gastrointestinal tract and identify underlying mechanisms of action.  In vitro and 
ex vivo, PEA and CBD prevented inflammation-induced permeability, and these effects 
were mediated by different receptors but similar intracellular pathways, and associated 
with changes in claudin, AQP and receptor expression. We then measured the excretion of 
sugar probes in vivo using an aspirin-induced pro-inflammatory model, with or without 
600mg PEA or 600mg CBD, in healthy volunteers.  Aspirin increased the LMR suggesting 
an increase in intestinal permeability, and this was prevented by both CBD and PEA.  
Together, these findings suggest that CBD and PEA decrease intestinal permeability, and 
may have future therapeutic use in IBD.  
We chose to examine the effect of CBD and PEA on the transfer of FD4 and FD10 
dextrans as these molecules are of a similar size to that of lipopolysaccharide from 
Escherichia Coli and pseudomonas species (20-40Å) 25,26.  PEA and CBD both reduced 
FD4 and FD10 transfer across Caco-2 membranes after an inflammatory protocol, 
blocked by PPARα and CB1 antagonism respectively, in line with previous reports 18,27.  
We hypothesized that there may be additive effects if applied simultaneously, but found 
this not to be the case.  Looking at the intracellular mechanisms of action, we found that 
inhibition of PKA, ERK/MEK and adenylyl cyclase prevented the actions of both drugs, 
suggesting that, although the membrane receptors of CBD and PEA are different, they 
exert their actions through similar intracellular pathways and hence demonstrate no 
additive effects.  This is the first report of the signalling pathways through which PEA 
acts in human colonic mucosa , and is in line with those explored in murine colitis 
models where PEA in acts through phosphorylation of ERK 28, and in neuronal tissue 
where it acts through PKA 29.  Similarly, our findings match previously described CBD 
actions at CB1 through adenylyl cyclase 5.   
We hypothesized that permeability changes caused by inflammation may be due to 
transcriptional changes in tight junction (TJ) proteins such as claudin, as changes in the 
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presence of these paracellular proteins have been shown in active Crohn’s disease 30.  
TJs are composed of two transmembrane proteins, occludin and claudin, with a third 
adjacent protein, the junctional adhesional molecule, within the inter-cellular space.  
These proteins are fused to identical molecules on neighbouring epithelial cells at which 
point the intercellular space is sealed around a charged pore.  The flux of material 
through this paracellular pore is determined by TJ structure, dependent on claudin type 
31.  Claudin-2 increases the permeability of the TJ, whereas claudin-5 and -8 decrease 
permeability 32. We found inflammation had no effect on mRNA for claudin proteins in 
Caco-2 cultures, and this was uninfluenced by PEA or CBD treatment.  We compared 
these findings with experimentally inflamed human colonic tissue, finding a decrease 
claudin-5 mRNA in response to inflammation and that this change was prevented by 
treatment with CBD.  Claudin-5 is highly expressed in the human colon, and acts to 
strengthen the mucosal barrier by decreasing permeability though cysteine residues 33.  
Inflammation is known to cause a decrease in the presence of claudin-5 and promotes 
increased permeability across mucosal types, hence this may be a mechanism by which 
CBD affects permeability 30,34.  We also found PEA decreased the transcription of claudin-
3, a protein providing a barrier function by decreasing permeability to charged ions in 
the healthy colon 35. The finding that PEA may decrease this transcription in human 
colon, yet decreasing hyperpermeability in Caco-2 cultures suggests that either the role 
of claudin-3 in the gut is incompletely understood, or that PEA does not simply affect 
permeability in terms of pore formation.  In support of our findings, Zeissig and 
colleagues (2007) found that claudin-3 expression is unaffected by Crohn’s disease 30, 
however in cell culture experiments, expression is reduced by TNFα treatment 36, but not 
by IL-13 35.  As no other reports have examined the effect of cannabinoids on claudin 
expression in human tissue, we are unable to determine if the effect of PEA on claudin-3 
is a mechanism by which permeability may be affected, and this requires further study. 
AQPs have been found to have an increasingly important role in both permeability to 
water and the immune response, therefore we hypothesized that changes in the 
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expression of two AQPs, AQP3 and AQP4 may be a mechanism by which cannabinoids 
affect permeability.  These proteins allow transport of water and solute through epithelial 
barriers via a transcellular route.  Similarly to TJs, epithelial AQP populations may 
change dynamically in response to varying physiological environments 37.   AQP3 
expression in the ileum is reduced in IBD, which was suggested as a mechanism to 
reduce oxidative stress through limiting water loss 38, although it has been shown that 
knockdown of AQP3 paradoxically impairs gut barrier function and increases permeability 
39.  We found that in Caco-2 cells, inflammation increased levels of membrane-bound 
AQP3, which was prevented both by PEA and CBD.  Conversely, in human tissue, the 
inflammatory protocol alone had no effect on AQP3 levels, whereas in the presence of 
the inflammatory protocol and PEA or CBD, AQP3 levels were increased. Previous work 
demonstrated that PEA and CBD are not anti-inflammatory in Caco-2 cultures, but do 
prevent the increased secretion of pro-inflammatory cytokines in human colonic tissue 
40. A potential mechanism therefore for PEA and CBD on the inflammatory response may 
be through upregulation of functional membrane-bound AQP3 and glycerol uptake, 
although this may not be the direct mechanism through which permeability is affected in 
Caco-2 cultures 41.  Further study is required examining the effect of CBD and PEA on 
glycerol uptake in conjunction with AQP3 expression in the human colon.   
AQP4 is known not to contribute to water transfer in the gut, as knock-down of the 
channel does not affect permeability 42, however there is evidence suggesting AQP4 
plays a role in the immune response of the colonic mucosa as AQP4 is upregulated in 
colonic mucosa of IL-10 knock out mice 43.  In Caco-2 cells we found no change in 
membrane bound AQP4 expression in response to inflammation, but up regulation in 
expression caused by PEA and CBD treatment.  In comparison with experimentally 
inflamed human colonic tissue, inflammation increased the presence of AQP4, which was 
not affected by PEA or CBD, although in the absence of inflammation these levels were 
reduced compared to vehicle alone.  The absence of an immune cell-mediated response 
to inflammation in Caco-2 cells may explain the difference between the two culture 
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models’ response to TNFα and IFNγ.  As AQP4 expression was reduced in human tissue 
compared to vehicle, it may be possible that prophylactic administration of CBD and PEA 
may change the response to inflammation.  We were unable to examine the effect of PEA 
and CBD on other AQP subtypes in this study, however this does pose a future avenue of 
experimentation for cannabinoid and cannabinoid-like compounds. 
It has been previously demonstrated that the expression of CB1 and CB2 receptors on the 
gut epithelium, immune cells and enteric nervous system change with inflammation 44,45.  
As PEA has been shown to alter the expression of these receptors in mice, we 
hypothesized that PEA and CBD might affect their expression (and of other molecular 
targets of cannabinoids) in experimentally inflamed human colon 11,28.  Surprisingly we 
did not find any effect of PEA or CBD on the expression of these two receptors both in 
Caco-2 and human explant models.  However, in both Caco-2 cultures and human colon 
we found a significant decrease in the expression of TRPV1 in response to inflammation, 
in line with previous reports 11.  In both cell culture and explant tissue models CBD 
prevented these falls, whereas PEA only prevented falls in TRPV1 expression in Caco-2 
cultures.  We also found that PPARα expression was increased by inflammation, but this 
was not affected by PEA or CBD treatment.  No other receptors were affected by 
inflammation.  The absence of change in CB1 or CB2 transcription is interesting, and 
contradicts existing evidence that CB1 and  CB2 both are upregulated in biopsies from 
IBD patients 45.  One possible explanation for this difference is the role of the enteric 
nervous system.  Peripherally restricted cannabinoid agonists have been shown not to 
prevent inflammatory changes in murine colitis, suggesting that cannabinoid action at 
the central nervous system is crucial to their effect on gut inflammation46.  This was 
supported by a study from Esposito et al., demonstrating that PEA may act directly on 
enteric glial cells rather than on mucosal immunocytes 28.  We may suggest that our 
normal tissue, which is no longer innervated by the enteric nervous system, did not 
therefore undergo any nerve-mediated changes in receptor expression.  Alternatively, 
these differences could also be explained by the presence of a secondary immune 
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response in ex vivo tissue, compared to in vitro Caco-2 cultures, possessing no 
specialised immune response, such as macrophages. This presents further evidence that 
the gut is dependent centrally on endocannabinoid tone for the immune response and 
barrier function. 
Clinically, permeability in vivo is not measured, however experimentally, it may be 
estimated by the ingestion of probe molecules which undergo urinary excretion.  
Administering two sugars which are absorbed and excreted at differential rates avoids 
confounding factors such as delayed gastric emptying, differing volumes of distribution , 
intestinal transit time and varying renal clearance 47.  D-mannitol is passively absorbed 
by the small intestine at a steady rate in health. Lactulose, a larger molecule, is not 
normally absorbed in health, but is passively absorbed during inflammatory intestinal 
episodes 48.  As both compounds undergo similar degradation in the gut, and regular 
excretion, the urinary lactulose to mannitol ratio (LMR) gives a measure of intestinal 
permeability. This ratio has previously been used to calculate intestinal permeability in 
Crohn’s disease, where lactulose absorption proportionally increases to the absorption of 
D-mannitol 49.  We have shown that aspirin causes an approximate 20-fold increase in 
LMR, in line with previously published reports 48.  It has been hypothesized that the 
mechanism by which increased permeability to sugars occurs is through inhibition of 
cyclooxygenase production, and therefore a decrease in mucosal prostaglandin 
production 50.   We found that PEA and CBD both decreased the concentrations of these 
sugars, and therefore may have achieved this through inhibiting cyclooxygenase 
production or by manipulation of membrane-bound proteins or receptors. Although we 
have not proven the mechanism in this study, we have shown for the first time in 
humans, that these compounds can reduce intestinal permeability in vivo and may 
potentially be of clinical use in IBD. 
There are several limitations to this study. Although high dose aspirin was used to increase 
in the absorption and excretion of ingested probes, this may not be a reliable simulation 
of gut inflammation. Therefore, the effects of PEA and CBD may not translate clinically.  
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Alternative models have been used to induce a state of hyperpermeability which may 
resemble clinical disease more closely.  One study administered LPS to healthy human 
subjects, successfully increasing the absorption of orally administered polyethylene glycol 
51.  However, all 14 participants developed the systemic inflammatory response syndrome, 
becoming haemodynamically unstable and requiring medical care.  In light of these risks, 
small phase 2 clinical trials examining the effect of CBD and PEA in IBD may now be 
considered.  Secondly, 6 of 10 samples in the PEA cohort were found to contain mannitol 
levels which were below the level of quantification using our LC-MS method.  Therefore, 
ratios of lactulose to mannitol were not possible to calculate for these 6 participants and 
were excluded, which may exaggerate group differences.  It is not clear if mannitol levels 
were undetectable because of PEA administration or due to an error in the administration 
of sugar probes or quantification of sugars at LCMS.  If this were due to a PEA effect this 
would have implications for the clinical use of PEA, as this would mean that it is highly 
permeability-decreasing.  This will be the subject of further study in our research group. 
In conclusion, we have demonstrated for the first time in humans that PEA and CBD 
prevent increases in permeability in the inflamed gut, and may do so through changes in 
AQP, TJ and receptor expression. These data add the growing body of data demonstrating 
the anti-inflammatory and permeability-reducing effects of PEA and CBD in the 
gastrointestinal tract 19. This holds significant promise for the development of future 
intestinal therapies treating disorders of increased intestinal permeability such as IBD.  
Their clinical effects should now be assessed in phase 1 and phase 2 clinical trials.    
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Figure 1: The Effects of PEA, applied basolaterally, and CBD, applied apically, on the 
permeability of Caco-2 monolayers in response to 24 hr exposure to TNFα and IFNγ 
measured by transfer of fluorescent dextrans (A:FD4 B:FD10 C:FD10 PEA & CBD). Raw 
data is expressed as the mean fluoescence per group +/- SEM. N=8 per condition. Data 
was analyzed by two-way ANOVA using Dunnett’s post hoc test comparing against the 
vehicle control (**** p<0.0001). 
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Figure 2: The effects of PEA (basolateral, A) and CBD (apical, B) on the permeability of 
Caco-2 monlayers in response to 24 hr exposure to TNFα and IFNγ in  the presence of 
various receptor anatgonists, measured by transfer of fluorescent dextrans (FD10).  Raw 
data is expressed as the mean fluoescence per group +/- SEM. N=8 per condition. Data 
was analyzed by two-way ANOVA using Dunnett’s post hoc test comparing against the 
vehicle control (*** p<0.001, **** p<0.0001).
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Figure 3: The effects of CBD (apical, A and C) and PEA (basolateral, B and D) on the 
permeability of Caco-2 monolayers in response to 24 hr exposure to TNFα and IFNγ in  
the presence of various protein inhibitors (KT5720, L-NAME and LY294002: A and C, and 
PD88059, SQ22536 and G06983: B and D), measured by transfer of fluorescent 
dextrans (FD10).  Raw data is expressed as the mean fluoescence per group +/- SEM. 
N=8 per condition. Data was analyzed by two-way ANOVA using Dunnett’s post hoc test 
comparing against the vehicle control (**** p<0.0001). 
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Figure 4. The effects of PEA and CBD on the expression of mRNA levels for tight 
junction proteins in response to a 24 hr inflammatory procotol in cultured Caco-2 cells 
(A=claudin 3, C= claudin 5), and human colonic tissue (B=claudin 3, D=claudin 5), 
measured by multiplex. Data is presented as percentage change from vehicle per plate 
+/- SEM, n=8 (A&C) and n=7 (B&D) per condition. Data was analysed by one-way 
ANOVA comparing against vehicle (* p<0.05, **p<0.01).   
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Figure 5.   The effects of PEA and CBD on the expression of mRNA levels for receptor 
proteins in response to a 24 hr inflammatory procotol in cultured Caco-2 cells (A=TRPV1, 
C=PPARα), and human colonic tissue (B=TRPV1, D=PPARα), measured by multiplex. 
Data is presented as percentage change from vehicle per plate +/- SEM, n=8 (A&C) and 
n=7 (B&D) per condition. Data was analysed by one-way ANOVA comparing against 
vehicle (* p<0.05, ****p<0.0001), or against inflammation († p<0.05).  
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Figure 6. The effects of PEA and CBD on levels of membrane bound AQP3 in Caco-2 
cultures (A) and human colonic mucosa (C) and AQP4 in Caco-2 cultures (B) and human 
colonic mucosa (D) in response to an inflammatory protocol, measured by ELISA. Raw 
data is expressed as mean protein levels per group +/- SEM. N=6-8 per condition. Data 
were analysed by one-way ANOVA comapring agianst vehicle (* p<0.05, ** p<0.01, 
***p<0.001, **** p<0.0001) or inflammation (†† p<0.05, ††††p<0.0001). 
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Figure 7. The concentration ratios of urinary lactulose and mannitol over time in healthy 
participants treated with aspirin and either placebo, CBD or PEA, measured by LC MS.  
Results are expressed as mean ratios +/- SEM.  Time points between groups were 
compared using two-way ANOVA using Dunnett’s multiple comparisons test comparing to 
placebo at the same time point (*p<0.05, **p<0.01, ***p<0.001). 
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Table 1. Urinary concentrations of lactulose and mannitol in healthy volunteers receiving 
aspirin and placebo (n=10), CBD (n=10) and PEA (n=4) therapy.  Results are expressed 
as mean concentrations +/- standard deviation.  Concentrations were compared to 
baseline using repeated measures ANOVA and Dunnett’s multiple comparison test 
(*<0.05, **<0.01, ***<0.001 ****<0.0001). LMR – Lactulose: mannitol ratio.
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Supplementary figure 1. The effects of PEA and CBD on the expression of mRNA levels 
for tight junction proteins in response to a 24 hr inflammatory procotol in cultured Caco-
2 cells (A=claudin 1, B=claudin 2, C=claudin 4, D=claudin 7, E=claudin 9), and human 
colonic tissue (F=claudin 1, G=claudin 2, H=claudin 4, I=claudin 7, J=claudin 8), 
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measured by multiplex. Data is presented as percentage change from vehicle per plate 
+/- SEM, n=8 (A-E) and n=7 (F-J) per condition. Data was analysed by one-way ANOVA 
comparing against vehicle.   
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Supplementary figure 2. The effects of PEA and CBD on the expression of mRNA levels 
for receptor in response to a 24 hr inflammatory procotol in cultured Caco-2 cells 
(A=PPARδ, B=PPARδ, C=CB1, D=CB2, E=GPR55, F=GPR119), and human colonic tissue 
(G= PPARδ, H= PPARδ, I= CB1, J= CB2, K=GPR55, L=GPR119), measured by multiplex. 
Data is presented as percentage change from vehicle per plate +/- SEM, n=8 (A-F) and 
n=7 (G-L) per condition. Data was analysed by one-way ANOVA comparing against 
vehicle.   
 
